Spots Global Cancer Trial Database for immunotoxin
Every month we try and update this database with for immunotoxin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | NCT00460447 | Acute Myeloid L... Allogeneic Tran... | Gemtuzumab Ozog... | 18 Years - 70 Years | University Hospital Carl Gustav Carus | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | NCT03436732 | Mesothelioma | LMB-100 SEL-110 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| RFT-5-dgA in Patients With Metastatic Melanoma | NCT00314093 | Metastatic Mela... | RFT5pdgA | 18 Years - | University of Texas Southwestern Medical Center | |
| Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | NCT00924170 | Adult T-Cell Le... | LMB-2 Fludarabine Cyclophosphamid... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | NCT01362790 | Mesothelioma Adenocarcinoma ... Pancreatic Neop... | Pentostatin Cyclophosphamid... SS1(dsFv)PE38 -... SS1(dsFv)PE38 -... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | NCT02798536 | Mesothelioma | LMB-100 nab-paclitaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | NCT04034238 | Neoplasms With ... Epithelioid Mes... Cholangiocarcin... Adenocarcinoma,... | LMB-100 Tofacitinib Mesothelin Expr... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma | NCT02839681 | Lung Neoplasms | Anetumab Ravtan... Blood test | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | NCT02798536 | Mesothelioma | LMB-100 nab-paclitaxel | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial | NCT02219893 | Colorectal Neop... | MOC31PE Immunot... | 18 Years - | Oslo University Hospital | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease | NCT00457860 | Leukemia | Immunotoxin the... CAT-8015 immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | NCT02810418 | Neoplasms Pancreatic Neop... | LMB-100 Nab-Paclitaxel Mesothelin Expr... LMB-100 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT02556346 | Chronic B-cell ... Small Lymphocyt... | MT-3724 MT-3724 MT-3724 MT-3724 MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial | NCT02219893 | Colorectal Neop... | MOC31PE Immunot... | 18 Years - | Oslo University Hospital | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
